Target intelligence / Profile preview

Sperm-egg fusion protein Juno (JUNO)

Target
JUNO
Molecular classification
Receptor, Glycosylphosphatidylinositol (GPI)-anchored protein, Folate receptor family (FR family)
01

Overview

Sperm-egg fusion protein Juno (JUNO), also called the IZUMO1 receptor, is a glycosylphosphatidylinositol (GPI)-anchored receptor expressed on the surface of mammalian oocytes. It was originally identified as folate receptor 4 (FOLR4/FR-delta), but unlike other folate receptors, it does not bind folate due to the lack of a conserved folate-binding pocket. Instead, JUNO is essential for mammalian fertilization: it specifically mediates adhesion of sperm to the egg by binding to the sperm-specific protein IZUMO1, forming a unique and indispensable ligand-receptor pair for gamete recognition. This interaction is required for the initial physical contact (adhesion) between gametes; disruption or genetic deletion of either partner (JUNO or IZUMO1) in mouse models causes complete infertility due to failure of sperm-egg fusion, although it does not result in broader developmental or somatic abnormalities[2][4]. JUNO displays structural similarity with the folate receptor family but has evolved a fertilization-specific adhesive function[2][3][4]. There are no known drugs targeting JUNO, and its only well-established disease relevance is infertility caused by genetic deficiency or dysfunction[4].

Other names
IZUMO1 receptorIZUMO1RFolate receptor 4FOLR4FR-deltaFolbp3Probable folate receptor deltaFertilization factor on oocyte membraneEgg IZUMO receptor
02

Mechanism of action

Not applicable (No drugs directly target JUNO; functionally, it mediates the binding of IZUMO1 on sperm to enable gamete adhesion and subsequent fertilization)

03

Biological functions

Sperm-egg recognitionGamete membrane adhesionEssential mediator of mammalian fertilization
04

Disease associations

Infertility (due to loss-of-function or genetic deficiency)Other (no strong indication of other disease associations)
05

Safety considerations

Not applicable (targeting would likely block fertilization completely; genetic loss ablates fertility but no established adverse effects outside reproductive biology)
06

Interacting drugs

None known (no approved drugs or clinical candidates directly target this protein for therapeutic purposes as of now)
07

Biomarkers

Potential: Female infertility biomarker (experimental, as loss of JUNO results in non-fertilizable oocytes)No established clinical biomarkers based on JUNO

Beyond the preview

Go deeper on Sperm-egg fusion protein Juno (JUNO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sperm-egg fusion protein Juno (JUNO).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call